Ibrance (palbociclib) Letter of Medical Necessity
Ibrance (palbociclib) prior authorization requires documentation of HR+/HER2- status and the planned combination partner. Newer CDK4/6 inhibitors may be preferred on some formularies.
FDA-Approved Indications
- ● HR+/HER2- metastatic breast cancer (with aromatase inhibitor or fulvestrant)
Why Ibrance Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Receptor status not documented
- 2. Combination partner not specified
- 3. Step therapy through Verzenio or Kisqali
What to Include in a Ibrance Letter of Medical Necessity
Document HR+ (ER and/or PR positivity), HER2- status, line of therapy, planned combination partner (AI or fulvestrant), prior endocrine therapies, and the rationale for palbociclib selection.
Key clinical evidence to cite:
- ✓ PALOMA-1, PALOMA-2, PALOMA-3
Relevant guidelines:
- 📖 NCCN Breast Cancer Guidelines
- 📖 ASCO MBC Guidelines
Ibrance Prior Authorization Criteria
Standard criteria across major US payers for Ibrance. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy through Verzenio or Kisqali
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Ibrance
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Ibrance Prior Authorization FAQ
Why was my Ibrance prior authorization denied?
The most common denial reasons for Ibrance are: Receptor status not documented; Combination partner not specified; Step therapy through Verzenio or Kisqali.
What should a Ibrance Letter of Medical Necessity include?
Document HR+ (ER and/or PR positivity), HER2- status, line of therapy, planned combination partner (AI or fulvestrant), prior endocrine therapies, and the rationale for palbociclib selection.
Which payers cover Ibrance?
Ibrance is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.